Want to see IN:LALPATHLAB full AI Analyst Report?
Top Page
Dr. Lal PathLabs Limited
(LALPATHLAB)
Select Model
Select Model
Rating:74Outperform
Price Target:
₹2,114.00
▲(20.34% Upside)
Action:Reiterated
Date:08/06/26
The score is driven primarily by strong financial performance (low leverage and solid cash generation), supported by bullish technical trend signals. The main constraint is valuation: the high P/E and modest yield reduce the margin of safety, and technical indicators suggest the stock is currently overbought.
Positive Factors
Conservative balance sheet
Very low leverage (D/E ~0.08) and a multi-year downtrend in debt bolster financial flexibility. This durable strength reduces refinancing and solvency risk, supports opportunistic M&A or lab expansion, and allows continued investment through downturns without stressing cash flows.
Negative Factors
Margin compression
Sharp gross-margin decline and lower net margin in FY2026 signal structural pressure on profitability. If cost inflation, pricing erosion, or adverse test-mix trends persist, the firm’s return on capital and ability to self-fund growth will be impaired over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet
Very low leverage (D/E ~0.08) and a multi-year downtrend in debt bolster financial flexibility. This durable strength reduces refinancing and solvency risk, supports opportunistic M&A or lab expansion, and allows continued investment through downturns without stressing cash flows.
Read all positive factors
Dr. Lal PathLabs Limited (LALPATHLAB) vs. iShares MSCI India ETF (INDA)
Market Cap
₹319.77B
Dividend Yield0.84%
Average Volume (3M)3.61K
Price to Earnings (P/E)58.7
Beta (1Y)0.55
Revenue Growth14.29%
EPS Growth5.55%
CountryIN
Employees5,206
SectorGeneral
Sector StrengthN/A
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)32.44
Shares Outstanding167,637,770
10 Day Avg. Volume2,182
30 Day Avg. Volume3,614
Financial Highlights & Ratios
PEG Ratio12.69
Price to Book (P/B)8.73
Price to Sales (P/S)7.93
P/FCF Ratio40.94
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)37
Revenue Forecast (FY)₹32.01B
Dr. Lal PathLabs Limited Business Overview & Revenue Model
Company Description
Dr. Lal PathLabs Limited is a leading provider of diagnostic and related health assessment services, operating both domestically in India and across international borders. The company manages a comprehensive network of laboratories dedicated to co...
How the Company Makes Money
Dr. Lal PathLabs primarily makes money by charging fees for diagnostic testing services performed in its laboratories. Its core revenue stream is pathology and clinical laboratory testing, where samples collected from patients (via company-owned p...
Dr. Lal PathLabs Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
90
Very Positive
Cash Flow
84
Very Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 28.91B | 27.63B | 24.61B | 22.27B | 20.17B | 20.87B |
| Gross Profit | 15.69B | 11.61B | 16.38B | 14.62B | 12.87B | 15.85B |
| EBITDA | 9.13B | 8.54B | 7.89B | 6.78B | 5.32B | 6.13B |
| Net Income | 5.42B | 5.05B | 4.87B | 3.58B | 2.39B | 3.45B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 31.46B | 27.17B | 24.56B | 23.86B | 23.53B |
| Cash, Cash Equivalents and Short-Term Investments | 13.31B | 13.32B | 11.65B | 9.43B | 8.14B | 6.82B |
| Total Debt | 0.00 | 1.99B | 1.57B | 2.47B | 4.20B | 5.32B |
| Total Liabilities | -25.41B | 6.05B | 5.10B | 5.71B | 6.86B | 8.10B |
| Stockholders Equity | 25.41B | 25.08B | 21.73B | 18.49B | 16.66B | 15.08B |
Cash Flow | ||||||
| Free Cash Flow | 1.90B | 5.35B | 5.25B | 4.84B | 4.11B | -294.49M |
| Operating Cash Flow | 3.24B | 7.02B | 5.69B | 5.35B | 4.56B | 4.47B |
| Investing Cash Flow | -3.88B | -4.88B | -3.03B | -242.69M | -2.87B | -4.49B |
| Financing Cash Flow | -1.13B | -2.63B | -3.34B | -4.14B | -2.83B | 1.36B |
Dr. Lal PathLabs Limited Technical Analysis
Positive
1756.70
Price Trends
1683.85
Positive
1566.16
Positive
1512.34
Positive
Market Momentum
67.81
Negative
74.30
Negative
81.20
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:LALPATHLAB, the sentiment is Positive. The current price of 1756.7 is below the 20-day moving average (MA) of 1783.90, above the 50-day MA of 1683.85, and above the 200-day MA of 1512.34, indicating a bullish trend. The MACD of 67.81 indicates Negative momentum. The RSI at 74.30 is Negative, neither overbought nor oversold. The STOCH value of 81.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:LALPATHLAB.
Dr. Lal PathLabs Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹27.18B | 34.09 | ― | 0.16% | 14.22% | 7.17% | |
74 Outperform | ₹319.77B | 58.73 | ― | 0.63% | 14.29% | 5.55% | |
73 Outperform | ₹92.18B | 33.76 | ― | 1.65% | 21.09% | 65.51% | |
72 Outperform | ₹120.82B | 63.46 | ― | 0.21% | 23.64% | 29.96% | |
71 Outperform | ₹138.06B | 79.88 | ― | 0.23% | 19.49% | 20.50% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹17.10B | 16.86 | ― | 0.51% | 7.75% | 30.21% |
* General Sector Average
IN:LALPATHLAB
Dr. Lal PathLabs Limited
1,927.20
337.06
21.20%
IN:KRSNAA
Krsnaa Diagnostics Limited
558.90
-272.67
-32.79%
IN:METROPOLIS
Metropolis Healthcare Ltd.
562.55
66.06
13.31%
IN:THYROCARE
Thyrocare Technologies Ltd
597.90
157.36
35.72%
IN:VIJAYA
Vijaya Diagnostic Centre Ltd.
1,365.85
310.43
29.41%
IN:VIMTALABS
Vimta Labs Limited
642.30
-5.21
-0.80%
Dr. Lal PathLabs Limited Corporate Events
Dr. Lal PathLabs Publishes Q1 FY27 Earnings Call Transcript
Jul 30, 2026
Dr. Lal PathLabs Limited has released the transcript of its Q1 FY27 earnings conference call, held on July 24, 2026, in line with disclosure requirements under SEBI’s listing regulations. The call, lasting one hour and featuring the executiv...
Dr. Lal PathLabs Discloses Completion of Independent Director’s Tenure
Jul 26, 2026
Dr. Lal PathLabs Limited has announced that independent director Gurinder Singh Kalra has completed his tenure on the board as of the close of business on July 26, 2026, and consequently ceased to serve as an independent director from that date. T...
Dr. Lal PathLabs Sets July 25 Virtual AGM, Shares FY 2025-26 Annual Report Access Details
Jul 1, 2026
Dr. Lal PathLabs Limited has notified shareholders that its 32nd Annual General Meeting will be held on July 25, 2026, via video conferencing or other audio-visual means, in line with regulatory guidelines from Indian authorities. The company has ...
Dr. Lal PathLabs Files Q4 and FY26 Earnings Call Transcript With Exchanges
May 6, 2026
Dr. Lal PathLabs Limited has submitted to the Indian stock exchanges the official transcript of its Q4 and full-year FY26 earnings conference call, held on April 30, 2026, in compliance with SEBI’s disclosure regulations. The call, led by CE...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.